Czechia vs Dominican Republic: Prevalence rate of hypertension in men aged 30-79
Czechia
49.1
in 2019
Dominican Republic
49
in 2019
Czechia rank
17th
Dominican Republic rank
18th
Prevalence rate of hypertension in men aged 30-79 over time
- Czechia
- Dominican Republic
How they compare
Czechia currently reports 49.1 against 49 in Dominican Republic, a difference of 0.1.
Across all 30 years both countries report, Czechia has been ahead every year.
Czechia ranks 17th and Dominican Republic ranks 18th of 195 countries.
Czechia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Czechia | Dominican Republic | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 48.46 | 42.53 | 5.93 | Czechia |
| 2000s | 48.54 | 46.53 | 2.01 | Czechia |
| 2010s | 49.31 | 48.76 | 0.55 | Czechia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Czechia or Dominican Republic?
- Czechia, at 49.1 against 49 in Dominican Republic as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Czechia and Dominican Republic?
- 0.1, with Czechia ahead.
- How many years of comparable data are there for Czechia and Dominican Republic?
- 30 years are reported by both, from 1990 to 2019.
- How do Czechia and Dominican Republic rank globally for prevalence rate of hypertension in men aged 30-79?
- Czechia ranks 17th and Dominican Republic ranks 18th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.